Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.

PLoS One · 2023 · PMC9858091 · PMID 36662739

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Other studies also report few adverse events related to evolocumab, and a decreasing trend in injection-site reactions with longer duration of evolocumab use [ 20 , 22 , 25 ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.